Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Above 50-Day Moving Average of $2.74

Minerva Neurosciences, Inc. (NASDAQ:NERV)’s share price crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $2.74 and traded as high as $3.16. Minerva Neurosciences shares last traded at $3.15, with a volume of 8,434 shares trading hands.

Analysts Set New Price Targets

NERV has been the subject of several research reports. HC Wainwright dropped their price objective on shares of Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating for the company in a research note on Thursday, May 2nd. StockNews.com assumed coverage on Minerva Neurosciences in a research report on Thursday. They issued a “sell” rating for the company.

Minerva Neurosciences Price Performance

The business has a 50-day moving average of $2.74 and a 200-day moving average of $4.67. The company has a market capitalization of $22.02 million, a P/E ratio of -0.70 and a beta of 0.13.

Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.07. Sell-side analysts predict that Minerva Neurosciences, Inc. will post -1.89 EPS for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.